1-5 of 5
Douglas MacDonald
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3–Knockin Mice

Elena Burova, Aynur Hermann, Jie Dai, Erica Ullman, Gabor Halasz, Terra Potocky, Seongwon Hong, Matt Liu, Omaira Allbritton, Amy Woodruff, Jerry Pei, Ashique Rafique, William Poueymirou, Joel Martin, Douglas MacDonald, William C. Olson, Andrew Murphy, Ella Ioffe, Gavin Thurston, Markus Mohrs
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2019) 18 (11): 2051–2062.
https://doi.org/10.1158/1535-7163.MCT-18-1376
Published: 01 November 2019
View article titled, Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human <em>PD-1xLAG-3</em>–Knockin Mice
Open the PDF for Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human <em>PD-1xLAG-3</em>–Knockin Mice in another window
Includes: Supplementary data
Journal Articles

Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice

Elena Burova, Aynur Hermann, Janelle Waite, Terra Potocky, Venus Lai, Seongwon Hong, Matt Liu, Omaira Allbritton, Amy Woodruff, Qi Wu, Amanda D’Orvilliers, Elena Garnova, Ashique Rafique, William Poueymirou, Joel Martin, Tammy Huang, Dimitris Skokos, Joel Kantrowitz, Jon Popke, Markus Mohrs, Douglas MacDonald, Ella Ioffe, William Olson, Israel Lowy, Andrew Murphy, Gavin Thurston
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (5): 861–870.
https://doi.org/10.1158/1535-7163.MCT-16-0665
Published: 02 May 2017
View article titled, Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human <em>PD-1</em> Knock-In Mice
Open the PDF for Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human <em>PD-1</em> Knock-In Mice in another window
Includes: Supplementary data
Journal Articles

Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs

Julian Andreev, Nithya Thambi, Andres E. Perez Bay, Frank Delfino, Joel Martin, Marcus P. Kelly, Jessica R. Kirshner, Ashique Rafique, Arthur Kunz, Thomas Nittoli, Douglas MacDonald, Christopher Daly, William Olson, Gavin Thurston
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (4): 681–693.
https://doi.org/10.1158/1535-7163.MCT-16-0658
Published: 02 April 2017
View article titled, Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
Open the PDF for Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs in another window
Includes: Supplementary data
Journal Articles

Abstract A131: Rapid constitutive internalization and degradation of prolactin receptor (PRLR) is associated with potent cell killing by PRLR antibody drug conjugates (ADC)

Julian Andreev, NIthya Thambi, Frank Delfino, Joel Martin, Marcus P. Kelly, Jessica R. Kirshner, Douglas MacDonald, Nicholas Popadopoulos, Willian Olson, Gavin Thurston
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A131.
https://doi.org/10.1158/1535-7163.TARG-15-A131
Published: 01 December 2015
View article titled, Abstract A131: Rapid constitutive internalization and degradation of prolactin receptor (PRLR) is associated with potent cell killing by PRLR antibody drug conjugates (ADC)
Journal Articles

ERBB3/HER2 Signaling Promotes Resistance to EGFR Blockade in Head and Neck and Colorectal Cancer Models

Li Zhang, Carla Castanaro, Bo Luan, Katie Yang, Liangfen Fan, Jeanette L. Fairhurst, Ashique Rafique, Terra B. Potocky, Jing Shan, Frank J. Delfino, Ergang Shi, Tammy Huang, Joel H. Martin, Gang Chen, Douglas MacDonald, John S. Rudge, Gavin Thurston, Christopher Daly
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (5): 1345–1355.
https://doi.org/10.1158/1535-7163.MCT-13-1033
Published: 05 May 2014
View article titled, ERBB3/HER2 Signaling Promotes Resistance to EGFR Blockade in Head and Neck and Colorectal Cancer Models
Open the PDF for ERBB3/HER2 Signaling Promotes Resistance to EGFR Blockade in Head and Neck and Colorectal Cancer Models in another window
Includes: Supplementary data